Abstract | OBJECTIVE: DESIGN: Prospectic, case-control study. PATIENTS/ENVIRONMENT: 15 inpatients meeting 3 main criteria: 1) ACE therapy for past erythrocytosis, 2) actual erythrocytosis, 3) symptomatic increase of haematocrit (Hct). INTERVENTION: The treatment has been divided into 3 consecutive phases of 30 days each: 1) lisinopril (5 mg/die), 2) theophylline (4 mg/kg/die), 3) association of 2 drugs. MEASUREMENTS: The evaluations were scheduled at the beginning and every month and consisted of renal function control, haemochromocytometric exam, serum level of folates, B12 vitamin and erythropoietin (EPO), iron level, cyclosporinemia, as well as clinic control and adverse events detection. RESULTS: A significative decrease of Hct values and a decrease of serum erythropoietin values was observed in patients treated with lisinopril. Patients treated with theophylline showed a significant reduction of Hct values causing a reduction of erythropoietin serum level in 8/13 patients. Lisinopril and theophylline administered in combination presented a significant decrease of Hct values, while EPO values diminished compared to basal values. CONCLUSIONS:
|
Authors | A D'Amelio, D Bonucchi, P Patruno, M Ballestri, F Mastrangelo |
Journal | Minerva cardioangiologica
(Minerva Cardioangiol)
Vol. 45
Issue 11
Pg. 567-72
(Nov 1997)
ISSN: 0026-4725 [Print] Italy |
Vernacular Title | Trattamento dell'eritrocitosi post-trapianto: confronto tra lisinopril e teofillina. |
PMID | 9549290
(Publication Type: Clinical Trial, Clinical Trial, Phase II, Comparative Study, English Abstract, Journal Article, Review)
|
Chemical References |
- Cardiotonic Agents
- Vasodilator Agents
- Theophylline
- Lisinopril
|
Topics |
- Cardiotonic Agents
(therapeutic use)
- Hematocrit
- Humans
- Kidney Transplantation
(adverse effects)
- Lisinopril
(therapeutic use)
- Polycythemia
(drug therapy, etiology)
- Theophylline
(therapeutic use)
- Vasodilator Agents
(therapeutic use)
|